Astellas/UMN's cell cultured flu vaccine edges nearer possible '15 nod
This article was originally published in Scrip
Executive Summary
The Japanese venture UMN Pharma and partner Astellas have completed dosing in two ongoing Phase III trials with a cell cultured candidate flu vaccine, taking the product a step closer to a possible launch in Japan in 2015.